Solving Kids’ Cancer is not just our name, it’s our mission. We focus on aggressive childhood cancers with low survival rates—because Every Kid Deserves to Grow Up. Solving Kids' Cancer helps accelerate new, next-generation treatments, including immunotherapy, cancer vaccines, and new drugs by applying an understanding of the entire childhood cancer research landscape to wisely invest in innovative projects.
We extend our reach globally to fully understand the research landscape so that we may influence and strengthen the science, resulting in more cures for children. Solving Kids' Cancer fosters the development of innovative clinical trials that bring more effective treatments to children both in the U.S., Europe and beyond.
Solving Kids’ Cancer finds, funds, and advocates for breakthrough treatment options to cure children with the most fatal childhood cancers.
The inspiration for John London in co-founding Solving Kids' Cancer belongs solely to his daughter, Penelope, who once told him "I want no one to feel yucky, Daddy." Those words drove both John and his wife, Catherine, to make sure that no other families suffer the loss his family had to endure with the passing of Penelope. As Chairman of the Board of Directors, John has primary responsibilities with SKC that include leadership and overall management of organizational governance, compliance, donor cultivation, and fundraising. John also serves as a strategic advisor in all areas of therapeutic development. He has an MBA from The Wharton School of Business, University of Pennsylvania and a Bachelor of Arts from Brown University.
Scott co-founded SKC in 2007 as a tribute to his son, Hazen Kennedy, who was diagnosed with neuroblastoma at age three. Hazen was Scott's inspiration for creating Solving Kids' Cancer in part because Hazen wanted to become a scientist when he grew up in order to help people by creating new medicines. As Executive Director, Scott is integrally involved in the identification, funding, and management of the organization's scientific programs. Before co-founding SKC, Scott worked in marketing at CDW in Chicago and then at Pfizer in New York City. He also founded a New York City theatre and sightseeing business called Manfreakinhattan. Scott has a Bachelor of Science in Chemistry and Psychology from Indiana University and a MBA from the Asian Institute of Management
Board of Directors
John London co-founded Solving Kids' Cancer in honor of his daughter Penelope, who once told him "I want no one to feel yucky, Daddy." He is Board Chair of Solving Kids’ Cancer and serves as a strategic advisor in all areas of therapeutic development. He has an MBA from The Wharton School of Business, University of Pennsylvania, and a Bachelor of Arts from Brown University.
Scott Kennedy co-founded Solving Kids’ Cancer as a tribute to his son Hazen, who was diagnosed with neuroblastoma at age 3. As Executive Director, Scott is integrally involved in the identification, funding, and management of the organization's scientific programs. He has a BS in Chemistry and Psychology from Indiana University and an MBA from the Asian Institute of Management.
Khalil Barrage is a Managing Director at Invus, based in New York. He joined Invus in 2003 and established its Public Equity activity. Since its inception, Invus Public Equity has concentrated its investments in the emerging innovative biotech companies. Prior to joining Invus, he worked at The Olayan Group in New York and ran their US equity portfolio for 15 years. He holds a BA in Economics from the American University of Beirut. He is a member of the board of Protagenic and Celtaxsys. As part of his philanthropic engagement, Khalil serves on the board of the Children of Armenia Fund and Solving Kids’ Cancer.
Hearn Jay Cho, MD
Dr. Hearn J. Cho is an Associate Professor of Medicine, Hemotology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai Medical Center where he also has a practice that specializes in Hematology-Oncology. Dr. Cho earned his doctoral degree in immunology at Cornell University Medical College, followed by a postdoctoral research fellowship in immunology at the University of California, San Diego. Dr. Cho's research is focused on utilizing the body's immune system to develop patient specific vaccines and other treatments that destroy tumor cells and prevent them from returning. His research support development of personalized clinical approaches.
Lindy Gad has been involved with childhood cancer causes since 2006 when her daughter, today a long-term cancer survivor, was diagnosed with high-risk neuroblastoma. Lindy was instrumental in the creation of Y-mAbs Therapeutics Inc., a leading Immuno-Oncology company focused on pediatric cancer founded by her husband Thomas Gad. Today, Lindy is a philanthropist who resides in New York City with her husband and six children and continues to be very involved in pediatric cancer research and care.
Michael’s daughter, Bianca, was diagnosed with ETMR in 2016, a grade IV brain cancer which she has been fighting ever since. Michael is a Vice President at T. Rowe Price and focuses on European small-cap equity. Prior to T. Rowe Price, he worked at Fidelity Investments. Michael holds a BA from the University of Chicago and an MBA from Columbia Business School. He is a dual French/Brazilian citizen and currently lives in London with his wife and two daughters.
Julia is a Principal at TCV, focusing on the firm’s fundraising and investor relations activities. She brings global fundraising experience in private equity across the technology and emerging markets growth sectors. Prior to joining TCV, Julia was Managing Director at Autonomy Capital in New York. She has also worked in private equity at Silver Lake in New York and was the Head of IR for Vinci Partners. She began her career at J.P. Morgan in New York.
Julia holds masters degrees in economics and finance from the European Business School, Oestrich-Winkel and the Copenhagen Business School. A pediatric cancer research advocate, Julia dedicates significant time to the non-profit scientific field. Julia also carries a deep passion for adventure, including climbing Mount Everest … twice.
Mark N. Savoye is a Vice President, New Payments Business at MasterCard. He joined MasterCard in 2008. Prior to joining MasterCard, Mark served as a Director at American Express. Mark holds a BS degree from New York University Stern School of Business in Marketing and International Business. Mark serves on the board of directors for Madison Strategies and for the Maina Foundation.
Eyal is a New York based Manager in the Assurance practice of Ernst & Young LLP. He has over seven years of experience in the nonprofit and health industries primarily performing audits for nonprofit providers and related entities, which include accountable care organizations, collection agencies, and foundations. Eyal leads a local team of health focused individuals with a variety of experiences across the industry. In addition to serving as SKC board treasurer, Eyal also mentors NYC youth through the iMentor program.
Channing Stave, PhD
Channing Stave, Ph.D., is Chief Operating Officer of Newristics, a marketing and market research consulting firm focusing on Life Sciences. Prior to co-founding Newristics, he led the Strategies and Market Insights team at Express Scripts (formerly Medco). He has also held senior positions at Pfizer and IBM. He is a founding board member of Solving Kids’ Cancer and currently serves as Secretary. In addition, he is Co-President of the Board of Directors for Camp Zeke and serves on the board of Madison Strategies Group. He holds a BA from Columbia University and a MA and Ph.D. in Organizational Psychology from New York University.
Scientific Advisory Board
Hearn Jay Cho, MD, PhD
Mount Sinai School of Medicine
Multiple Myeloma Research Foundation
Christopher DeRenzo, MD
St. Jude's Children's Research Hospital
Andras Heczey, MD
Baylor College of Medicine
Texas Children's Hospital
Mark Kieran, MD, PhD
Clinical Trial Lead, Pediatrics Program, Oncology Clinical Development
Rimas J. Orentas, PhD
Seattle Children's Research Institute
Director of Scientific Integration
Stephen S. Roberts, MD
Memorial Sloan Kettering Cancer Center
The Andrew McDonough B+ Foundation honors the life of 14-year-old Andrew who battled leukemia before leaving us on 7/14/2007. Andrew’s B+ blood type became his family’s and friend’s motto throughout his fight against childhood cancer — to “Be Positive.” The B+ Foundation is about kids helping kids fight cancer -- by providing financial and emotional support to families of children with cancer, and by funding critical, cutting-edge childhood cancer research.
Committed to continuing Catherine’s fight, The Catherine Elizabeth Blair Memorial Foundation is focused on research and treatment to support the development of new treatments that are less toxic and less painful for children, and still effective at annihilating this vicious disease.
The EVAN Foundation was established in memory of Evan Lindberg who bravely battled neuroblastoma for four years before passing away at the age of 7 in 2010. The Foundation funds research aimed at fostering new treatment options for children with neuroblastoma, and sponsors patient-wellness programs for childhood cancer patients enduring long and difficult stays in the hospital.
It is our dream at “Fishin’ for the Cure” to one day live in a world where no child has to suffer from the painstaking battle of cancer...that one day, there will be hope and there will be a cure! We collaborate with like-minded nonprofits to help fund more research projects and assist families in our local communities who are affected by childhood cancers.
The mission of the Fitzgerald Cancer Fund is to battle neuroblastoma better by finding and funding less toxic treatments for neuroblastoma that focus on high quality of life for patients and by financially assisting families who have a child in treatment for neuroblastoma.
Joining Against Cancer in Kids was established in 2008 to bring therapies in the UK and improve existing treatment protocols for children with neuroblastoma as well as research into new treatments. The initiative was supported by officers of the Metropolitan Police Service, and also by family and friends of Jack Brown.
The James Fund for Neuroblastoma Research was established at Sick Kids Hospital, where all funding goes directly to research and investigation efforts for neuroblastoma therapies. The James Fund represents Canada on the Advances in Neuroblastoma Research (ANR) group, an international think tank of neuroblastoma scientists raising the bar on neuroblastoma research worldwide.
The Make Some Noise: Cure Kids Cancer Foundation was established by a child with cancer with one purpose in mind: to fund pediatric cancer research. To that end, the foundation serves as a vehicle to secure private funding to distribute to research facilities and promote awareness through its fund raising activities. The designation of funds to various research facilities is cancer specific and based on the foundation's annual evaluation of the latest research.
Solving Kids' Cancer UK helps children access potentially life-saving treatment, whilst supporting research that not only aims to introduce new treatments but also bring existing internationally available options here to the UK. We support parents by sharing the most current resources available for neuroblastoma treatments and providing access to other parents who want to share their knowledge and experiences
Pierce Alexander Phillips is the inspiration for Scott and Brandi Phillips, and fuels the Pierce Phillips Charity. PPC exists to make progress in the fight against neuroblastoma and other forms of childhood cancers by directing funds to research and trials that can increase survivorship now and that will eventually lead to a cure for the most innocent of cancer victims.
The Ronan Foundation is dedicated to raising awareness and funding cutting edge research for childhood cancer. We are committed to funding clinical trials to reduce the number of children affected by childhood cancer, increase survival rates and minimize long term medical and psychological effects of treatment.
The Ty Louis Campbell Foundation funds innovative research and clinical trials specifically geared toward the treatment of the deadliest childhood cancers (including brain and spinal cord tumors). TLC seeks less toxic, more effective treatments that are specifically designed for children fighting cancer.
Band of Parents is a grassroots, nonprofit organization that funds innovative research and clinical trials for neuroblastoma, helping increase the survival rate for this childhood cancer. We are a support network for the newly diagnosed and their families as they go through treatment. Our goal as parents is to fast track a cure using less toxic, targeted therapies.
A Kids’ Brain Tumor Cure Foundation (aka PLGA Foundation), founded in 2007, is dedicated to finding more effective, less toxic and less punishing treatments for eradicating low grade glioma brain cancer in children. Our goal is to accelerate the pace of promising scientific pediatric brain tumor research through: Raising funds to support state of the art scientific research and raising awareness with scientists, doctors, lay people and pharmaceutical companies about the lack of existing effective treatments and a cure.
The Children’s Neuroblastoma Cancer Foundation (CNCF) is a non-profit national health organization committed to finding a cure for neuroblastoma through research, education, awareness and advocacy. The premier source for neuroblastoma information and resources, CNCF initiatives educate the public about a disease dramatically lacking in awareness and funding. It serves as an advocate for families, as well as a liaison between healthcare providers and families.